USA Samsung Bioepis is expanding in the US biosimilars market, with ten FDA approvals so far, seven assets in development, and an ambitious target of 20 products on the market by 2031. Tom Newcomer, SVP and Head of US Commercial, sets out why quality and supply reliability, rather than low prices,…
USA Generics and biosimilars serve as the financial bedrock preventing the US healthcare system from collapsing under the weight of escalating drug prices. “Generic drugs account for nearly 90 percent of all prescriptions filled in the United States, yet they consume only about 12 percent of total US prescription drug spending,”…
Global Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity is enormous, as is the potential impact for government coffers and patients. Can Europe maintain its position as the industry’s…
USA If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution into a dedicated biosimilars developer with ten FDA approvals and a long-term commitment to improving affordability and access. He highlights…
Global A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader in biosimilar adoption, South Korea is rapidly emerging as a powerhouse, leveraging strong government support and industry investment. However, a…
Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…
Korea A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new 300-million-euro plant; EuBiologics’s World Health Organization (WHO) prequalification for its cholera vaccine, and Samsung Biologics’ record Q1 earnings. South…
Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…
South Korea As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top CDMO organizations, with revenues of USD 1.21 billion in 2021, is no exception. In response to increased demand, the firm…
Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…
South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…
Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…
See our Cookie Privacy Policy Here